Yazar "Aksoy N." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Action plan to regain unnecessary deferred blood donors due to malaria risk in Turkey
    (2012) Degirmenci A.; Döşkaya M.; Caner A.; Nergis Ş.; Gül K.; Aydinok Y.; Ertop T.; Aksoy N.; Korkmaz M.; Alkan M.Z.; Üner A.; Gürüz Y.
    Malaria was expected to be a major problem during blood donation in Turkey due to existence of malaria cases in southeastern region of Turkey. The present study aimed for the first time, to investigate malaria in "donors deferred for malaria risk" and to determine the regional rates of malaria deferral in Turkey. Blood samples were collected from several Blood Banks of southeastern provinces where local malaria cases still exist and from Blood Bank of Ege University Medical School (EUMS) located in western Turkey where malaria is eradicated decades ago. Plasmodium spp. and specific antibodies were investigated by stained smears, antigen detection, PCR and ELISA. Among the donors deferred for malaria risk, Plasmodium spp. were not detected by microscopy, PCR or antigen detection. Seroprevalances were 2% and 3.92% in western and southeastern regions, respectively. Rate of donor deferral for malaria risk was 0.9% in EUMS and deferrals were exclusively because of travel to southeastern Turkey. In southeastern provinces, deferrals were mainly due to malaria like fever history. The present study first time assessed regional rates of donor deferral due to malaria risk in Turkey. Previously, malaria was expected to be a major problem during blood donation in Turkey due to existence of malaria cases in southeastern region of Turkey. The results of the study showed that 97% of the deferrals were unnecessary. In conclusion, to reduce unnecessary donor deferrals in Turkey, in addition to comprehensive questioning for malaria history, the usage of a malaria antibody screening method should be initiated prior to deferral decision. © 2012 Elsevier Ltd.
  • Küçük Resim Yok
    Öğe
    Effect of fluconazole prophylaxis on fungal colonisation in ICU patients
    (1994) Moral A.R.; Tumbay E.; Ulusoy B.; Aksoy N.; Cevik A.; Inci R.
    In this study, the effect of fluconazole prophylaxis on the incidence of fungal (yeast) colonization in multidisciplinary ICU patients were investigated. A total of 252 patients were mycologically screened in the first week of their hospitalization and followingly once every week. The specimens studied were blood (from venous route and from central venous catheter) urine catheter, endotracheal tubes, oral cavity, nares, skin and rectal swabs. The fungus isolated was candida. 91 received fluconazole 100 mg/day IV or enterally for prophylaxis and 161 served as the control group. Total number of samples in study was 2852 and 1723 of these samples were from the control group, 27.5% being positive. 1129 samples were taken from the prophylaxis group while 18.8% were positive. In conclusion, prophylactic treatment with 100 mg/day fluconazole significantly decreases the incidence of fungal colonization in ICU patients (p<0.01).
  • Küçük Resim Yok
    Öğe
    The role of microsatellite instability to predict clinical benefit from irinotecan-based regimens in metastatic colorectal cancer
    (2008) Artaç M.; Pehlivan S.; Akcan S.; Pehlivan M.; Gelen T.; Itirli G.; Aksoy N.; Özdogan M.; Savaş B.; Samur M.; Bozcuk H.
    The aim of our study was to assess the relationship between microsatellite instability (MSI) and the clinical outcome in metastatic colorectal cancer (CRC) patients treated with irinotecan-based regimens. We assessed best objective response, progression free survival (PFS) and overall survival (OAS) in relation to MSI analysis that was performed using BAT-25, BAT-26, D5S346, D2S123, D17S250 markers in normal and tumor DNA. The best objective response was significantly and negatively related with the D17S250 (an adjacent locus to p53) microsatellite marker (p=0.047). However, MSI score was not related with the best objective response (p=0.88). There was again no relationship between PFS, OAS and MSI score. In conclusion, this study allowed us to establish in a prospective study design that MSI status did not predict survival in metastatic colorectal cancer patients treated with irinotecan-based regimens.